RIL
ZNTL icon

Rothschild Investment LLC’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Rothschild Investment LLC’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-70
Closed -$111 – 3206
2025
Q1 		$111 Sell
70
-250
-78% -$539 ﹤0.01% 2956
2024
Q4 		$970 Buy
320
+150
+88% +$492 ﹤0.01% 2233
2024
Q3 		$626 Buy
170
+150
+750% +$545 ﹤0.01% 2405
2024
Q2 		$82 Buy
20
+10
+100% +$112 ﹤0.01% 2767
2024
Q1 		$158 Buy
+10
New +$138 ﹤0.01% 1872

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Rothschild Investment LLC's ZNTL Position: Q2 2025 in Review

Rothschild Investment LLC sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2025, closing a stake of 70 shares — an estimated $111 sold.

Rothschild Investment LLC first reported a position in ZNTL in Q1 2024 and held it in 5 quarters. The position peaked at $970 in Q4 2024. 117 funds tracked by Wall St. Rank hold ZNTL as of Q2 2025.

  • Rothschild Investment LLC reported no remaining Zentalis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Rothschild Investment LLC sold 70 Zentalis Pharmaceuticals shares in Q2 2025, an estimated $111.
  • Rothschild Investment LLC first reported a position in Zentalis Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • Rothschild Investment LLC's Zentalis Pharmaceuticals position peaked at $970 in Q4 2024.
  • 117 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2025.

Based on Rothschild Investment LLC's 13F filing for Q2 2025, filed 11 Aug 2025.